Anti-cancer therapy often causes premature ovarian insufficiency and infertility as the ovarian follicle reserve is extremely sensitive to chemotherapy drugs, such as cisplatin. Various fertility preservation methods have been explored for women, especially prepubertal girls undergoing radiotherapy and chemotherapy due to cancer. In recent years, mesenchymal stem cell-derived exosomes (MSC-exos) have been reported to play an important role in tissue repair and the treatment of various diseases. In the current study, we observed that human umbilical cord-derived MSC-exos (hucMSC-exos) after short-term culture improved follicular survival and development while receiving cisplatin treatment. Moreover, intravenous injection of hucMSC-exos improved ovarian function and ameliorated inflammatory environment within the ovary. The underlying mechanism of hucMSC-exos on fertility preservation was associated with the down-regulation of p53-related apoptosis and their anti-inflammatory function. Based on these findings, we propose that hucMSC-exos may be a potential approach to improve fertility in women diagnosed with cancer.
The effects of chemotherapy drugs on female reproduction were reported since the 1970s, which were initially associated with cyclophosphamide (CPM) treatment[1]. There is now ample evidence that cancer treatment can deplete the ovarian reserve, resulting in early menopause[2]. Chemotherapy-induced premature ovarian failure (POF) is a major long-term adverse effect of anti-cancer therapy. Therefore, the development of new approaches to preserve fertility for female patients, especially for those younger patients with a strong desire for childbearing who require chemotherapy drugs, is critical.
cis-diamminedichloroplatinum (Ⅱ) (CDDP) is a widely used and effective metal-based chemotherapeutic drug for many types of cancer, including cancers of testicule, ovary, breast, and lung[3]. It is often used in combination with other cytotoxic drugs. Chemotherapeutic drugs, such as CDDP[4], usually cause double-strand DNA damage, which may induce apoptosis in granulosa cells and oocytes. Females are born with a finite number of primordial follicles, most of which will remain dormant for decades until they are activated into the growing follicular pool[5]. Primordial follicles are very sensitive to the toxicity of chemotherapeutic agents, which may activate the PI3K/AKT signaling pathway that leads to the loss of primordial follicles[6–7]. Therefore, it is crucial to explore new approaches of protecting the reproductive reserve, while using chemotherapeutic drugs.
In the past decade, mesenchymal stem cells (MSCs) have attracted a great attention due to their reparative function and board therapeutic potential. Human umbilical cord-derived MSCs (hucMSCs) are a type of multipotent stem cell with many advantages, including wide availability, easy accessibility, low immunogenicity and high self-renewal ability[8]. To date, hucMSCs have been studied in clinical therapeutic trials. The stem cell therapy has also emerged as a new treatment for female infertility in recent years. Successful pregnancies have been reported in premature ovarian insufficiency (POI) patients who received hucMSC transplantation[9]. hucMSCs have also been shown to improve the reserve function of perimenopausal ovaries through a paracrine mechanism[10]. However, more research is needed to explore the underlying molecular mechanisms of hucMSCs and how they protect the ovarian reserve.
Many investigators have proved that MSCs secrete products, especially exosomes, to play key roles in tissue repair and healing. Exosomes are extracellular vesicles with a size rage of 30 to 150 nm, which are important in intercellular communication[11]. Similar to their cell source, stem cell-derived exosomes have shown therapeutic effects via their reparative and regenerative abilities. It has been shown that MSCs-derived exosomes (MSC-exos) have the same efficacy in tissue repair as MSCs. Recent studies have indicated the potential of hucMSC-derived exosomes (hucMSC-exos) in improving ovarian function in aged mice. However, the role of hucMSC-exos in protecting ovarian reserve and restoring ovarian function after chemotherapy remains unclear. Therefore, we aims to explore whether hucMSC-exos have an ameliorative effect on the damage to ovarian reserve after CDDP chemotherapy. Based on the therapeutic potential of exosomes, we believe that stem cell exosome therapy might represent a new strategy for protecting ovarian reserve during chemotherapy.
Materials and methods
Animals
Mice from the Institute of Cancer Research (ICR) were obtained from Nanjing Medical University and housed in the Animal Core Facility of Nanjing Medical University. All mice were maintained under a 12 h light/dark cycle at 22 ℃ with free access to food and water. Female ICR mice at day three were used for ovarian culture. All animal work was approved by the Committee on the Ethics of Animal Experiments at Nanjing Medical University. Superovulation was performed with one intraperitoneal injection of pregnant mare serum gonadotropin (PMSG, 5 IU; NSHF, Ningbo, Zhejiang, China) and followed by another injection of human chorionic gonadotropin (HCG, 5 IU; NSHF) 48 h later.
In vitro fertilization
Donor sperm were first collected from male mice into G-IVF media (Vitrolife, Goteborg, Sweden) and incubated under oil for 1 h at 37 ℃ in 5% CO2 for capacitation. Metaphase Ⅱ oocytes were then placed into 250 μL of media with sperm (2 × 105/mL to 3 × 105/mL) for fertilization. Six hours later, zygotes with clear pronuclei were transferred into fresh G-1 media (Vitrolife) overnight until the two-cell embryonic. The fertilized embryos were cultured in G-1 media for five days to the blastocyst stage.
The isolation and culture of hucMSCs
Fresh umbilical cords were collected from informed and voluntary mothers at Sir Run Run Hospital of Nanjing Medical University. The experiment protocol was approved by the Ethics of Committee of Nanjing Medical University. Briefly, umbilical cords were dissected into 1 mm3 small pieces and washed with phosphate buffered saline (PBS; Biosharp, Guangzhou, Guangdong, China) containing 100 U/mL penicillin and 100 mg/mL streptomycin (Biofil, Guangzhou, China) for three times. Then tissues were cultured in DMEM/F-12 that contained 10% fetal bovine serum (Gibco, Waltham, MA, USA) and 1% penicillin and streptomycin at 37 ℃ and 5% CO2.
The isolation and characterization of hucMSC-derived exosomes
Briefly, the cultured medium was removed and washed twice with PBS when hucMSC reached 60%–70% confluence. MSCs were then cultured with de-exosome medium for two days. The supernatants were collected and centrifuged at 300 g for 10 min at 4 ℃ and centrifuged at 2000 g for 10 min to remove dead cells. Then, supernatants were centrifuged at 10 000 g for 30 min to remove cell debris and supernatant was then centrifuged at 150 000 g for 90 min to acquire exosome pellets. The concentration and particle size were measured by nanoparticle tracking analysis (Particle Metrix, Germany). All procedures were performed at 4 ℃. Exosomes were incubated in 2% paraformaldehyde solution overnight for transmission electron microscopy analysis. Two microliters of the exosome solution were transferred onto a carbon-coated copper grid. Then, the grid was observed using a transmission electron microscope (Tecnai G2 Spirit BioTwin, FEI, Hillsboro, OR, USA).
In vitro mice ovary tissue culture
The ovarian culture-conditioned medium consists of MEM-α (Gibco) supplemented with 0.23 mmol/L pyruvic acid, 50 mg/L streptomycin sulfate, 75 mg/L penicillin G, 0.03 U/mL follicle-stimulating hormone, and 3 mg/mL bovine serum albumin. Cell culture medium of 0.4 mL was added to the bottom of each well, and the postnatal day-three (PD3) ovaries were isolated and cultured in inserts (Millipore, Billerica, MA, USA). Five ovaries were randomly distributed to the control and treated groups. Intact ovaries from PD3 female ICR mice were treated with PBS or CDDP (0.5 μg/mL in PBS; MCE, NJ, USA) combined with or without hucMSC-exos (20 μg/mL) for 24 h, and then transferred to the conditional medium for additional 96-h culture before collection for further analysis.
The uptake of hucMSC-exos by the cultured newborn ovaries
hucMSC-exos were labeled with PKH67 dye (green) (Sigma, St. Louis, MO, USA) at room temperature for 2 h and ultracentrifugated at 120 000 g for 90 min to remove un-conjugated dye. Labeled exosomes were incubated with PD3 ovaries for 24 h. After incubation, ovaries were collected and fixed in 4% formaldehyde for frozen sections. After staining nuclei with Hoechst 33342 (Invitrogen, Carlsbad, CA, USA), slides were observed and calculated by using a confocal laser scanning microscope (LSM, Zeiss, Oberkochen, Germany).
Follicle counting
For follicle counting, ovaries were collected and fixed in 10% formalin overnight. Then, the tissues were cut into serial sections (5 μm thick) and stained by hematoxylin and eosin. To evaluate follicular development, follicles were counted every five sections using the fractionator and nucleator principles[12]. The number of follicles of newborn ovaries was counted from mid-ovary sections. All sections were counted by two individuals.
Immunohistochemistry and immunofluorescence staining
For immunohistochemistry, sections were deparaffinized and rehydrated, endogenous peroxidase activity was further blocked in 3% hydrogen peroxide in methanol for 15 min. The antigen of ovarian sections were retrieved by high temperature (95 ℃) for 16 min in sodium citrate buffer (pH 6.0). Then the sections were blocked with goat serum for 60 min at room temperature (ZSGB-Bio, Beijing, China), and incubated with primary antibodies at 4 ℃ overnight. The sections were colored with diaminobenzidine (DAB) reagent. For immunofluorescence staining, the sections were incubated with secondary antibody (Alexa Fluor 488 or Alexa Fluor 594; Invitrogen) at 37 ℃ for 60 min followed by the incubation with Hoechst 33342 (Invitrogen).
Western blotting
Total protein was extracted from ovaries using RIPA buffer (Cat. #P0013B, Beyotime, Shanghai, China) containing 1% protease inhibitor (MCE). Proteins were separated by 10% SDS-PAGE and transferred into polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA, USA). The membranes were incubated with primary antibodies overnight at 4 ℃ after being blocked with Tris-buffered saline with Tween 20 (TBST) containing 5% nonfat dry milk for 60 min. The following primary antibodies were used: Alix (ZENBIO, Chengdu, Sichuan, China), TSG101 (Proteintech, Wuhan, Hubei, China), CD9 (Proteintech), β-tubulin (Abbkine, Wuhan, Hubei, China), γH2AX (abcam, Boston, MA, USA), BAX (CST, Danvers, MA, USA), p53 (CST), Cleaved caspase-3 (CST), Bcl-2 (Abclonal, Wuhan, Hubei, China). Then, the membranes were washed three times with TBST for 10 min and incubated with secondary antibodies for 60 min. The signals were obtained through enhanced chemiluminescence (Thermo Fisher Scientific, Carlsbad, CA, USA) on the Tanon 5200 analysis system (Tanon, Shanghai, China).
Real-time reverse transcription PCR
Total RNAs were isolated from ovaries using TRIzol reagent (Invitrogen). Total RNAs (500–1000 ng per reaction) were reverse transcribed into cDNAs by FastQuant RT Kit (TIANGEN Biotech, Beijing, China). Real-time reverse transcription PCR (qRT-PCR) was then performed by SYBR Green Mix (Applied Biological Materials, Vancouver, Canada) on an ABI StepOnePlus platform (Thermo Fisher Scientific). All primer sequences are listed in Supplementary Table 1 (available online). The specificity of PCR products was assessed by melting curve analyses.
Flow cytometric analysis
Cells were fixed in 4% paraformaldehyde with 0.25% Triton X-100 in PBS, and then incubated with primary antibodies at 4 ℃ for 2 h. Primary antibodies purchased from BD Verse (Franklin Lakes, NJ, USA) were used: PE Mouse Anti-Human CD90, APC Mouse Anti-Human CD105, FITC Mouse Anti-Human CD44, FITC Mouse Anti-Human CD34, FITC Mouse Anti-Human 45, and PE Mouse Anti-Human CD11b. After washing with PBST, cells were analyzed by flow cytometry (BD Verse). The data were further analyzed by FlowJo 7.0 software (BD, San Jose, CA, USA).
Statistics analysis
GraphPad Prism 9.0 and SPSS 20.0 were used to perform the Chi-square test. All data were expressed as mean ± standard deviation and analyzed using unpaired two-tailed Student's t-test for two treatment groups and one-way ANOVA followed by Bonferroni's post-hoc multiple comparison correction for multiple treatment groups. P < 0.05 was considered statistically significant.
Results
The isolation and identification of hucMSC-derived exosomes
Flow cytometry was performed to identify surface markers of hucMSCs, and the results showed that CD44, CD90, and CD105 were highly expressed in hucMSCs, while CD34, CD45, and CD11b were negatively expressed (Supplementary Fig. 1, available online). Then the exosome-specific markers Alix, TSG101, and CD9 in hucMSC-exos, isolated from culture supernatant of three to seven passages of hucMSC, were examined by Western blotting, and the results showed that Alix, TSG101, and CD9 were highly expressed in hucMSC-exos (Fig. 1A). Transmission electron microscopy analysis showed that the obtained hucMSCs-exos were in a round structure with double-layer membranes (Fig. 1B), and the particles had a typical size of 81 to 109 nm revealed by nanoparticle tracking analysis (Fig. 1C). These results suggested that exosomes were successfully isolated from hucMSC.
Figure
1.
Characterization of hucMSC-derived exosomes.
A: Exosome-specific markers Alix, TSG101, and CD9 expression in Exos and MSCs were examined by Western blotting. β-Tubulin was used as an internal control. B: Representative image of hucMSC-exos observed by transmission electron microscope. Scale bar: 100 nm. C: The size distribution and concentration of exosomes were assessed by nanoparticle tracking analysis. D: Exosomes were labeled with PKH67 and the nuclei stained with Hoechst 33342. Scale bar: 50 μm. Abbreviations: Exos, human umbilical mesenchymal stem cells derived exosomes; MSCs, mesenchymal stem cells.
hucMSC-derived exosomes reduced primordial depletion during cisplatin treatment in newborn mouse ovaries
To observe the uptake of hucMSC-exos in ovaries in vitro, hucMSC-exos were labeled with PKH67 dye for 24 h. As shown in Fig. 1D, PKH67 fluorescence signals were observed to be accumulated in oocytes. The results showed that hucMSC-exos could be uptaken by follicles in vitro. Several studies have shown that chemotherapy can destroy immature follicles like primordial follicles as well as secondary ones[13]. Newborn ovaries at PD3, which contain the mainly amount of ovarian reserve, were used to study the effects of hucMSC-exos on ovarian reserve protection during CDDP treatment. The results showed that CDDP treatment significantly reduced the volume of ovaries, compared with the control group, but hucMSC-exos treatment significantly attenuated CDDP-induced reduction of ovarian volume (Fig. 2A and 2B).
Figure
2.
Effects of hucMSC-exos on ovarian reserve after CDDP injury.
Ovaries at postnatal day three (PD3) female ICR mice were cultured with PBS, CDDP (0.5 μg/mL) or CDDP with hucMSC-exos (20 μg/mL) for 24 h, respectively. Then, all groups of ovaries were transferred to conditional medium for additional 96 h culture. A: Morphology of ovaries in the control, CDDP, and CDDP + hucMSC-exos groups. Scale bar: 1 mm. B: Comparison of ovarian relative volume among control, CDDP and CDDP + hucMSC-exos. C: Immunofluorescence staining of DDX4 (red) in ovaries of the control, CDDP, and CDDP + hucMSC-exos groups. Blue: Hoechst 33342. Scale bar: 50 μm. D: Distribution of primordial follicles (Primor) and growing follicles (Growing) in the control, CDDP, and CDDP + hucMSC-exos groups. E: Immunostaining of PCNA in follicles in the control, CDDP, and CDDP + hucMSC-exos groups. Scale bars: 50 μm. F: Relative intensityof PCNA in oocyte. Data are presented as mean ± SD in biological triplicate experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-tailed unpaired Student's t-test. Abbreviations: CDDP, cis-diamminedichloroplatinum (Ⅱ); Exos, human umbilical mesenchymal stem cells derived exosomes; PCNA, proliferating cell nuclear antigen; SD, standard deviation.
To assess follicular development, immunofluorescent staining of DEAD-box polypeptide 4 (DDX4) was used to localize oocytes. The results showed that the DDX4 staining could be clearly observed in primordial follicle cytoplasm (Fig. 2C). The number of follicles was counted from mid-ovary sections after treatments. We found a significant decrease in the number of both primordial and growing follicles in the ovaries of the CDDP group, compared with that of the control group, but hucMSC-exos treatment reduced CDDP-induced loss of primordial and growing follicles in ovaries (Fig. 2D). Immunohistochemistry staining of the proliferating cell nuclear antigen (PCNA) in ovaries showed a decreased PCNA expression and more abnormal oocytes in the CDDP-treated group, compared with the control group as well as the increased PCNA expression and less abnormal oocytes in the CDDP + hucMSC-exos group, compared with the CDDP group (Fig. 2E and 2F). These results indicated that CDDP treatment directly destroyed ovarian reserve and hucMSC-derived exosomes could protect primordial follicles to a certain extent.
hucMSC-exos treatment inhibited follicle apoptosis and DNA breakage in oocytes in vitro
Previous studies have reported that CDDP treatment leads to follicle apoptosis and DNA damage[14–15]. Immunofluorescence staining of phosphorylated histone H2AX (γH2AX), a marker of DNA damage, revealed a significant increase in the number of double-strand breaks (DSBs) in CDDP treated ovaries, which was reversed in ovaries of the CDDP + hucMSC-exos group (Fig. 3A and3B). Moreover, γH2AX expression detected by Western blotting was lower in the CDDP + hucMSC-exos group than in the CDDP group (Fig. 3C). These results suggested that hucMSC-exos could repair ovarian DNA double-strand damage.
Figure
3.
hucMSC-exos ameliorated CDDP-induced follicular apoptosis and DNA breakage in primordial oocytes.
Ovaries at post day three (PD3) female ICR mice were cultured with PBS, CDDP (0.5 μg/mL) or CDDP with hucMSC-exos (20 μg/mL) for 24 h, respectively. Then, all groups of ovaries were transferred to conditional medium for additional 96 h culture. A: γH2AX (red) and DDX4 (green) were marked with immunofluorescence staining in the control, CDDP, and CDDP + hucMSC-exos groups, respectively. The nuclei were stained with Hoechst 33342 (blue). Scale bar: 50 μm. B: Fluorescent intensity of γH2AX signal in ovaries of the control, CDDP, and CDDP + hucMSC-exos groups. C: γH2AX expression was measured using Western blotting in control, CDDP, and CDDP + hucMSC-exos groups. β-Tubulin was used as an internal control. D: TUNEL staining to detect apoptosis in ovaries of the control, CDDP, and CDDP + hucMSC-exos groups. Green: TUNEL signal; Blue: Hoechst 33342. Scale bar: 50 μm. E: Fluorescent intensity of TUNEL signal in ovaries of the control, CDDP, and CDDP + hucMSC-exos groups. F: Western blotting of γH2AX, Bcl-2, and Bax expression in ovaries of the control, CDDP, and CDDP + hucMSC-exos groups. β-Tubulin was used as an internal control. G-H: The expression intensity of Bcl-2 and Bax in ovaries of different groups. Data are presented as mean ± SD in biological triplicate experiments. **P < 0.01 and ***P < 0.001 by two-tailed unpaired Student's t-test. Abbreviations: CDDP, cis-diamminedichloroplatinum (Ⅱ); Exos, human umbilical mesenchymal stem cells derived exosomes; TUNEL, TdT-mediated dUTP-biotin nick end-labeling; SD, standard deviation.
The apoptosis level in ovaries was detected by TdT-mediated dUTP-biotin nick end-labeling (TUNEL) assay, and the results showed a higher level of apoptosis of granulosa cells and stromal cells in CDDP-treated ovaries, compared with the control group, but the apoptosis level was returned to that similar to the control group after hucMSC-exos treatment following CDDP challenge (Fig. 3D and3E). The gene Bcl2 and Bax play important roles in apoptosis[16]. The effects of CDDP and hucMSC-exos on Bcl-2/Bax apoptotic pathway in ovaries were analyzed by Western blotting. The results showed that Bcl-2/Bax ratio was significantly down-regulated in the CDDP group, compared with the control group, and up-regulated in the CDDP + hucMSC-exos group, compared with the CDDP group (Fig. 3F–3H). These results suggested that hucMSC-exos could preserve follicles by inhibiting oocyte DNA breakage and apoptosis in ovaries.
hucMSC-exos improved ovarian follicle function and restored fertility in CDDP-treated mice in vivo
A diagram scheme for in vivo experiment was shown in Fig. 4A. Briefly, three-week old female mice received intraperitoneal injection of CDDP for 10 days and intravenous injection of PBS or hucMSC-exos for two more weeks. hucMSC-exos were labeled with PKH67 dye for tracing, and a strong green fluorescent protein (GFP) signal was detectable in the ovarian medulla and surrounding follicles (Fig. 4B). Two weeks after PBS/exosomes injection, the ovarian volume of the CDDP + hucMSC-exos group was greater than that of the CDDP group (Fig. 4C). Total follicle counting showed a significant loss of follicle in the CDDP group and a retention of follicles in the CDDP + hucMSC-exos group (Fig. 4D). Follicles counting results revealed that, compared with controlled ovaries, the CDDP-treated ones revealed extreme damage in terms of follicular development, including a decreased follicle count at developmental stages and an increase in atretic follicles (Fig. 4E). In contrast, ovaries received hucMSC-exos treatment following CDDP challenge showed an obvious improvement in the number of growing follicles at different developmental stages compared with the CDDP group (Fig. 4E).
Figure
4.
hucMSC-exos improved follicular development rescue of ovulation of mature eggs and embryonic development.
Mice at three weeks of age were intraperitoneally injected with 2 mg/kg of CDDP or the same volumes of PBS for 10 days. For CDDP treated mice, some were intraperitoneally injected with hucMSC-exos while the others received the same volume of PBS for two more weeks (n = 7 in each group). A: Schema for PBS, CDDP and hucMSCs in vivo treatment. B: Green indicates PKH67-labeled exosomes that accessed the ovary site, and the nuclei were stained with Hoechst 33342 (blue). Scale bar: 100 μm. C: Ovarian size of the control, CDDP and CDDP + hucMSC-exos groups. D: Follicle counting of ovarian total follicles. E: Distribution of different stages of follicles with or without treatment of hucMSC-exos. F: The concentration of E2 in the control, CDDP and CDDP + hucMSC-exos groups. G: Numbers of ovulated oocytes in each group, five mice for each group. H: Embryonic development to blastocyst from ovulated eggs of treated mice following in vitro fertilization. Scale bar: 50 μm. I and J: Percentage of fertilization with two cells and blastocyst formation and hatching after in vitro fertilization. Data are presented as mean ± SD in biological triplicate experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-tailed unpaired Student's t-test. Abbreviations: CDDP, cis-diamminedichloroplatinum (Ⅱ); Exos, human umbilical mesenchymal stem cells derived exosomes; E2, estradiol; PBS, phosphate buffered saline; SD, standard deviation.
The concentration of serum estradiol (E2) was measured using an enzyme-linked immunosorbent assay. Compared with the control group, CDDP treatment induced a significant down regulation of E2 in the serum, which was attenuated by hucMSC-exos treatment (Fig. 4F). We then examined the function of hucMSC-exos for ovulation and mature egg production. After superovulation, an increased number of ovulated oocytes were harvested from the mice of the CDDP + hucMSC-exos group, compared with the CDDP group (Fig. 4G). These results suggested that the in vivo hucMSC-exos treatment improved oocyte retrieval.
Then, we evaluated the in vitro fertilization (IVF) ability of oocytes from each group. After IVF with the donor sperm, the rates of two-cell embryos to blastocysts in the CDDP group were reduced, but they were rescued by hucMSC-exos transplantation (Fig. 4H–4J). These results indicated that hucMSC-exos played a protection role in cisplatin-induced follicle damage and restored follicular development in vivo to enhance fertility.
hucMSC-exos protected granulosa cell from CDDP damage
In the neonatal mouse ovary culture model, we observed an increased level of apoptosis in early follicular granulosa cells after CDDP treatment. Therefore, we explored whether hucMSC-exos could improve follicle development by restoring granulosa cell function. The expression levels of granulosa cell-associated genes (i.e., Kitl and Amhr) in ovaries were detected by qRT-PCR. The results showed that the expression levels of Kitl and Amhr were significantly upregulated in ovaries of the CDDP + hucMSC-exos group, compared with the CDDP group (Fig. 5A). Immunostaining of PCNA showed that more positive signals were detected in granulosa cells in the CDDP + hucMSC-exos group, compared with the CDDP group (Fig. 5B). These results indicated that hucMSC-exos promoted granulosa cell proliferation and improved granulosa functions.
Figure
5.
The improvement of ovarian granulosa apoptosis in CDDP-treated ovaries.
Mice at three weeks of age were superovulated after PMSG and HCG treatment (n = 7 in each group). Then ovarian granulosa cells were isolated by microisstion of follicles and corpus luteum from the ovary. Granulosa cells were treated with PBS, CDDP (0.5 μg/mL) or CDDP with hucMSC-exos (20 μg/mL) for 24 h, respectively. A: Relative mRNA expression of Kitl and Amhr in the control, CDDP and CDDP + hucMSC-exos groups. B: Ovarian PCNA staining in various groups. Scale bar: 50 μm. C: TUNEL staining to detect apoptosis in ovaries of the control, CDDP and CDDP + hucMSC-exos groups. Green: TUNEL signal; Blue: Hoechst. Scale bar: 50 μm. D: Fluorescent intensity of TUNEL signals in ovaries of the control, CDDP and CDDP + hucMSC-exos groups. E-F: Bcl2 and Bax relative expression of granulosa cells in the control, CDDP and CDDP + hucMSC-exos groups. G-K: Western blotting and quantitative analyses of apoptosis-related proteins p53, cleaved caspase-3, caspase-3, Bcl-2, and Bax in the control, CDDP and CDDP + hucMSC-exos groups. β-Tubulin was used as an internal control. L: Immunostaining of cleaved-caspase3 in the control, CDDP and CDDP + hucMSC-exos groups. Scale bar: 50 μm. Data are presented as mean ± SD in biological triplicate experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-tailed unpaired Student's t-test. Abbreviations: CDDP, cis-diamminedichloroplatinum (Ⅱ); Exos, human umbilical mesenchymal stem cells derived exosomes; TUNEL, TdT-mediated dUTP-biotin nick end-labeling; SD, standard deviation.
Results of the TUNEL assay further demonstrated that apoptosis in the ovaries was increased in the CDDP group, compared with the control group, and decreased in CDDP + hucMSC-exos group, compared with the CDDP group (Fig. 5C and 5D). The apoptosis level in early granulosa cells was increased in the CDDP group. To demonstrate the protective role of hucMSC-exos against cells damage in the ovaries, we dissociated primary ovarian granulosa cells from ovaries and cultured them in vitro. The mRNA expression levels of anti-apoptosis gene Bcl2 and pro-apoptosis gene Bax in granulosa cells were detected by qRT-PCR. The results showed that Bcl2 expression was significantly increased in the CDDP + hucMSC-exos group, compared with the CDDP group, while Bax expression was significantly reduced in the CDDP + hucMSC-exos group, compared with the CDDP group (Fig. 5E and 5F). Western blotting was performed to detect the expression of apoptosis-related proteins in granulosa cells. Compared with the CDDP group, the expression levels of p53 and cleaved caspase-3 were down-regulated, and the Bcl-2 level was also up-regulated in the CDDP + hucMSC-exos group (Fig. 5G–5K). These results indicated a decrease in the level of apoptosis in the ovary after hucMSC-exos treatment. Similarly, immunohistochemistry staining of cleaved caspase-3 showed that hucMSC-exos treatment reduced cell apoptosis in the ovaries induced by CDDP (Fig. 5L). These results consistently showed that hucMSC-exos had a protective effect against CDDP-induced granulosa damage.
hucMSC-exos improved inflammatory environment in the ovaries
CDDP has been reported to induce pro-inflammatory signaling, which is associated with persisting markers of inflammation[17]. We next evaluated whether there were beneficial effects of hucMSC-exos on CDDP-treated ovaries. The distribution of M1-like macrophages was detected by immunofluorescence staining of inducible nitric oxide synthase (iNOS). The results showed the decreased positive signals for M1-like macrophages in the hucMSC-exos group, compared with the CDDP group (Fig. 6A and 6B). The results of immunofluorescence staining of F4/80 showed that macrophage infiltration in the ovaries was increased in the CDDP group, compared with the control group and decreased in the CDDP + hucMSC-exos group, compared with the CDDP group (Fig. 6C and6D). The results of qRT-PCR showed that hucMSC-exos treatment could significantly suppress CDDP-induced increase in the expression of pro-inflammatory genes, including Il1b and Il6 (Fig. 6E and 6F). Taken together, the results suggested that hucMSC-exos treatment could alter the inflammatory environment in CDDP-treated ovaries.
Figure
6.
hucMSC-exos changed ovarian inflammatory environment in CDDP-treated ovaries.
Mice at three weeks of age were intraperitoneal injected with 2 mg/kg of CDDP or the same volume of PBS for 10 days. For CDDP treated mice, one half of the mice were intraperitoneal injected with hucMSC-exos and the others received the same volume PBS for two more weeks (n = 6 in each group). A: Immunofluorescence staining of iNOS in ovaries of the control, CDDP and CDDP + hucMSC-exos groups. Green: iNOS; Blue: Hoechst 33342. Scale bar: 50 μm. B: iNOS fluorescence intensity in the control, CDDP and CDDP + hucMSC-exos groups. C: Immunofluorescence staining of F4/80 in ovaries of the control, CDDP and CDDP + hucMSC-exos groups. Green: F4/80; Blue: Hoechst 33342. Scale bar: 50 μm. D: Fluorescence intensity of F4/80 in the control, CDDP and CDDP + hucMSC-exos groups. E and F: Relative expression of Il1b and Il6 in ovaries of the control, CDDP and CDDP + hucMSC-exos groups. Data are presented as mean ± SD in biological triplicate experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-tailed unpaired Student's t-test. Abbreviations: CDDP, cis-diamminedichloroplatinum (Ⅱ); Exos, human umbilical mesenchymal stem cells derived exosomes; SD, standard deviation.
Women of childbearing age often experience POF and infertility due to the damaging effect of chemotherapy drugs, which are regular side effects of anti-cancer therapies. How to prevent POF and protect follicle pools among this population with fertility aspirations have received increasing attention. At present, the clinical application to prevent ovarian function damage by chemotherapy is not very extensive. The main current approaches to fertility preservation after chemotherapy include administration of sphingosine-1-phosphate[18], melatonin[19], and AS101[20–21]. In the current study, we proposed and proved that hucMSC-exos had a protective effect on follicular protection after chemotherapy (e.g., cisplatin) treatment. Additionally, in hucMSC-Exos-treated ovaries, we found follicle developmental restoration. hucMSC-exos significantly increased the number of eggs that ovulated from superovulated ovaries, as well as blastocyst formation. These findings are consistent with our previous reports about the fertility restoration in aged ovaries after hucMSC-exos administration[10]. Our findings suggest that hucMSC-exos may be another candidate to preserve ovarian reserve and improve ovarian function after CDDP chemotherapy.
As the most common chemotherapy drug, cisplatin is still the first-line chemotherapeutic drug for the treatment of several cancers, including breast cancer, and widely used in clinical treatment of hematologic and solid tumors in children and women of childbearing age. However, it is still unclear how is the mechanism of CDDP exposure in ovarian failure. There is a growing evidence that exposure to CDDP leads to follicular excessive consumption and loss[22]. The proposed mechanism of CDDP to damage follicles may be through the increase of DNA damage and the activation of apoptosis related genes, like P53 family, especially in immature follicles[23]. In the current study, the significant increase in γH2AX signals in CDDP-cultured ovaries indicates that cisplatin induces DSBs in oocytes, leading to ovarian reserve damage. Notably, a decrease in the number of DSB positive-labeled oocytes was observed after hucMSC-exos treatment. These findings suggest that hucMSC-exos treatment may repair DNA DSBs in oocytes. The observation likely explains why more primordial follicles preservation detected in newborn ovaries.
Studies have reported a pro-apoptosis function induced by CDDP[24]. p53 is a tumor suppressor protein that regulates cell growth by modulating its target genes P27, Bcl2, Bax, and Puma (the gene encoding p53 up-regulated modulator of apoptosis). In the current study, we observed that the apoptosis of granulosa cells and DSBs in oocytes increased after CDDP treatment, which is consistent with the effects of CDDP on the ovaries in a rat model[25]. Investigators have pointed out that the activation of p53 can induce apoptosis and cell migration[26]. Here, we found that hucMSC-exos up-regulated Bcl-2 protein expression and down-regulated cleaved caspase-3 protein expression to protect granulosa cells from CDDP injury. Moreover, hucMSC-exos reduced the apoptotic sign in ovarian follicles, which suggests hucMSC-exos may improve ovarian function. In our current study, we found that the expression of p53 was decreased in granulosa cell cultured by CDDP. After hucMSC-exos treatment, we were surprised to find that embryonic development after IVF was improved. It also indirectly demonstrates that hucMSC-exos improve follicular development by the restoration of granulosa function.
With the developments in stem cell therapy, many investigators focus on the use of adipose-derived MSCs or bone marrow-derived MSCs in the regeneration and functional recovery via experimental animal models[27–28]. Compared with other sources of stem cells, hucMSCs are the first choice for cell therapy due to their non-invasive isolation, low immunogenicity and the ability of fast self-renewal[29]. However, hucMSCs have relative limitations in the quantification of bioactive substances and the logistics for delivery in clinical therapies. Several investigators suggested that the culture medium of MSCs had therapeutic effects in POI murine models[30]. Compared with MSCs, exosome, a member of extracellular vesicles may be a better choice in the clinic, because of their low immunogenicity, high clinical safety and stable bioactivity[31]. Therefore, the application of MSC-exos is more effective and safer than the MSC therapy.
The successful maturation of oocytes is associated with systemic hormone regulation, granulosa cell function, and ovarian microenvironment. Similarly, the homeostasis of the perifollicular environment depends on the maintenance of multiple cells, including immune cells and stromal cells. CDDP induces a myriad of inflammatory cytokines and chemokines, including translocation factors, which lead to the production of tumor necrosis factor alpha (TNF-α), a pro-inflammatory cytokine that is actively involved in CDDP-induced inflammation. Therefore, we examined the expression of inflammatory factors in the ovaries after CDDP treatment. The expression of major proinflammatory cytokines IL-1β and IL-6 increased in CDDP-treated ovaries. The increased number of macrophages found in the ovary after CDDP treatment indicates that CDDP is correlated with a proinflammatory environment in ovaries. To be noted, hucMSC-exos improved ovarian follicular development, meanwhile the anti-inflammatory effects of hucMSC-exos were required for the amelioration of ovarian microenvironment and improved ovarian function in the CDDP-treated mice.
The molecular mechanism, involved in hucMSC-exos repair of the ovarian function, needs to be further explored. The active components in hucMSC-exos may regulate ovarian microenvironment. We will focus on what components of hucMSC-exos are involved in the recovery of ovarian function in future studies.
Ackonwledgements
None.
Fundings
This work is supported by the National Key Research and Development Program of China (Grant Nos. 2018YFC1003703 and 2018YFC1004203) and the National Natural Science Foundation of China (Grant No. 31871513).
Miller III JJ, Williams GF, Leissring JC. Multiple late complications of therapy with cyclophosphamide, including ovarian destruction[J]. Am J Med, 1971, 50(4): 530–535. doi: 10.1016/0002-9343(71)90341-X
[2]
Jayasinghe YL, Wallace WHB, Anderson RA. Ovarian function, fertility and reproductive lifespan in cancer patients[J]. Expert Rev Endocrinol Metab, 2018, 13(3): 125–136. doi: 10.1080/17446651.2018.1455498
[3]
Ho GY, Woodward N, Coward JIG. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies[J]. Crit Rev Oncol Hematol, 2016, 102: 37–46. doi: 10.1016/j.critrevonc.2016.03.014
[4]
Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts[J]. Chem Rev, 1999, 99(9): 2467–2498. doi: 10.1021/cr980421n
[5]
Spears N, Lopes F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection[J]. Hum Reprod Update, 2019, 25(6): 673–693. doi: 10.1093/humupd/dmz027
[6]
Yang Y, Zhao Y, Liao W, et al. Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment[J]. Neoplasia, 2009, 11(4): 313–324. doi: 10.1593/neo.81358
[7]
Maidarti M, Anderson RA, Telfer EE. Crosstalk between PTEN/PI3K/Akt signalling and DNA damage in the oocyte: implications for primordial follicle activation, oocyte quality and ageing[J]. Cells, 2020, 9(1): 200. doi: 10.3390/cells9010200
[8]
Ding D, Chang Y, Shyu WC, et al. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy[J]. Cell Transplant, 2015, 24(3): 339–347. doi: 10.3727/096368915X686841
[9]
Shareghi-Oskoue O, Aghebati-Maleki L, Yousefi M. Transplantation of human umbilical cord mesenchymal stem cells to treat premature ovarian failure[J]. Stem Cell Res Ther, 2021, 12(1): 454. doi: 10.1186/s13287-021-02529-w
[10]
Yang W, Zhang J, Xu B, et al. HucMSC-derived exosomes mitigate the age-related retardation of fertility in female mice[J]. Mol Ther, 2020, 28(4): 1200–1213. doi: 10.1016/j.ymthe.2020.02.003
[11]
He C, Zheng S, Luo Y, Wang B, et al. Exosome theranostics: biology and translational medicine[J]. Theranostics, 2018, 8(1): 237–255. doi: 10.7150/thno.21945
[12]
Flaws JA, Abbud R, Mann RJ, et al. Chronically elevated luteinizing hormone depletes primordial follicles in the mouse ovary[J]. Biol Reprod, 1997, 57(5): 1233–1237. doi: 10.1095/biolreprod57.5.1233
[13]
Lopes, F., et al. Single and combined effects of cisplatin and doxorubicin on the human and mouse ovary in vitro[J]. Reproduction, 2020, 159(2): p. 193–204. doi: 10.1530/REP-19-0279
[14]
Digby JLM, Vanichapol T, Przepiorski A, et al. Evaluation of cisplatin-induced injury in human kidney organoids[J]. Am J Physiol Renal Physiol, 2020, 318(4): F971–F978. doi: 10.1152/ajprenal.00597.2019
[15]
Freedman BS, Brooks CR, Lam AQ, et al. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids[J]. Nat Commun, 2015, 6: 8715. doi: 10.1038/ncomms9715
[16]
Edlich F. BCL-2 proteins and apoptosis: Recent insights and unknowns[J]. Biochem Biophys Res Commun, 2018, 500(1): 26–34. doi: 10.1016/j.bbrc.2017.06.190
[17]
Domingo IK, Latif A, Bhavsar AP. Pro-inflammatory signalling PRRopels cisplatin-induced toxicity[J]. Int J Mol Sci, 2022, 23(13): 7227. doi: 10.3390/ijms23137227
[18]
Morita Y, Perez GI, Paris F, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy[J]. Nat Med, 2000, 6(10): 1109–1114. doi: 10.1038/80442
[19]
Kerr JB, Hutt KJ, Cook M, et al. Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib[J]. Nat Med, 2012, 18(8): 1109–1174. doi: 10.1038/nm.2889
[20]
Carmely A, Meirow D, Peretz A, et al. Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice[J]. Hum Reprod, 2009, 24(6): 1322–1329. doi: 10.1093/humrep/den481
[21]
Maman E, Prokopis K, Levron J, et al. Does controlled ovarian stimulation prior to chemotherapy increase primordial follicle loss and diminish ovarian reserve? An animal study[J]. Hum Reprod, 2009, 24(1): 206–210. doi: 10.1093/humrep/den337
[22]
Nguyen QN, Zerafa N, Liew SH, et al. Loss of PUMA protects the ovarian reserve during DNA-damaging chemotherapy and preserves fertility[J]. Cell Death Dis, 2018, 9(6): 618. doi: 10.1038/s41419-018-0633-7
[23]
Bildik G, Akin N, Senbabaoglu F, et al. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro[J]. Hum Reprod, 2015, 30(12): 2912–2925. doi: 10.1093/humrep/dev257
[24]
Hirata Y, Takahashi M, Yamada Y, et al. trans-Fatty acids promote p53-dependent apoptosis triggered by cisplatin-induced DNA interstrand crosslinks via the Nox-RIP1-ASK1-MAPK pathway[J]. Sci Rep, 2021, 11(1): 10350. doi: 10.1038/s41598-021-89506-8
[25]
Yuksel A, Bildik G, Senbabaoglu F, et al. The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells[J]. Hum Reprod, 2015, 30(12): 2926–2935. doi: 10.1093/humrep/dev256
[26]
Huang SM, Tsai CF, Chen DR, et al. p53 is a key regulator for osthole-triggered cancer pathogenesis[J]. Biomed Res Int, 2014, 2014: 175247. doi: 10.1155/2014/175247
[27]
Zhang J, Guan J, Niu X, et al. Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis[J]. J Transl Med, 2015, 13: 49. doi: 10.1186/s12967-015-0417-0
[28]
Zhang B, Wang M, Gong AH, et al. HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing[J]. Stem Cells, 2015, 33(7): 2158–2168. doi: 10.1002/stem.1771
[29]
Li T, Xia M, Gao Y, et al. Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy[J]. Expert Opin Biol Ther, 2015, 15(9): 1293–1306. doi: 10.1517/14712598.2015.1051528
[30]
Ling L, Feng X, Wei T, et al. Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism[J]. Stem Cell Res Ther, 2019, 10(1): 46. doi: 10.1186/s13287-019-1136-x
Pan S, Yan H, Zhu J, et al. GYY4137, as a slow-releasing H2S donor, ameliorates sodium deoxycholate-induced chronic intestinal barrier injury and gut microbiota dysbiosis. Front Pharmacol, 2024, 15: 1476407.
DOI:10.3389/fphar.2024.1476407
2.
Jin YQ, Yuan H, Liu YF, et al. Role of hydrogen sulfide in health and disease. MedComm (2020), 2024, 5(9): e661.
DOI:10.1002/mco2.661
3.
Sun X, Wu S, Mao C, et al. Therapeutic Potential of Hydrogen Sulfide in Ischemia and Reperfusion Injury. Biomolecules, 2024, 14(7): 740.
DOI:10.3390/biom14070740
4.
Pagliaro P, Weber NC, Femminò S, et al. Gasotransmitters and noble gases in cardioprotection: unraveling molecular pathways for future therapeutic strategies. Basic Res Cardiol, 2024, 119(4): 509-544.
DOI:10.1007/s00395-024-01061-1
5.
Dugbartey GJ, Juriasingani S, Richard-Mohamed M, et al. Static Cold Storage with Mitochondria-Targeted Hydrogen Sulfide Donor Improves Renal Graft Function in an Ex Vivo Porcine Model of Controlled Donation-after-Cardiac-Death Kidney Transplantation. Int J Mol Sci, 2023, 24(18): 14017.
DOI:10.3390/ijms241814017
6.
Hu Q, Lukesh JC 3rd. H2S Donors with Cytoprotective Effects in Models of MI/R Injury and Chemotherapy-Induced Cardiotoxicity. Antioxidants (Basel), 2023, 12(3): 650.
DOI:10.3390/antiox12030650
7.
Farzaei MH, Ramezani-Aliakbari F, Ramezani-Aliakbari M, et al. Regulatory effects of trimetazidine in cardiac ischemia/reperfusion injury. Naunyn Schmiedebergs Arch Pharmacol, 2023, 396(8): 1633-1646.
DOI:10.1007/s00210-023-02469-7
8.
Khattak S, Rauf MA, Khan NH, et al. Hydrogen Sulfide Biology and Its Role in Cancer. Molecules, 2022, 27(11): 3389.
DOI:10.3390/molecules27113389
9.
Zhou M, Chen JY, Chao ML, et al. S-nitrosylation of c-Jun N-terminal kinase mediates pressure overload-induced cardiac dysfunction and fibrosis. Acta Pharmacol Sin, 2022, 43(3): 602-612.
DOI:10.1038/s41401-021-00674-9
10.
Zhang Y, Gong W, Xu M, et al. Necroptosis Inhibition by Hydrogen Sulfide Alleviated Hypoxia-Induced Cardiac Fibroblasts Proliferation via Sirtuin 3. Int J Mol Sci, 2021, 22(21): 11893.
DOI:10.3390/ijms222111893
11.
McCook O, Denoix N, Radermacher P, et al. H2S and Oxytocin Systems in Early Life Stress and Cardiovascular Disease. J Clin Med, 2021, 10(16): 3484.
DOI:10.3390/jcm10163484
12.
Testai L, Brancaleone V, Flori L, et al. Modulation of EndMT by Hydrogen Sulfide in the Prevention of Cardiovascular Fibrosis. Antioxidants (Basel), 2021, 10(6): 910.
DOI:10.3390/antiox10060910
13.
Wang WL, Ge TY, Chen X, et al. Advances in the Protective Mechanism of NO, H2S, and H2 in Myocardial Ischemic Injury. Front Cardiovasc Med, 2020, 7: 588206.
DOI:10.3389/fcvm.2020.588206
14.
Denoix N, McCook O, Ecker S, et al. The Interaction of the Endogenous Hydrogen Sulfide and Oxytocin Systems in Fluid Regulation and the Cardiovascular System. Antioxidants (Basel), 2020, 9(8): 748.
DOI:10.3390/antiox9080748
15.
Pieretti JC, Junho CVC, Carneiro-Ramos MS, et al. H2S- and NO-releasing gasotransmitter platform: A crosstalk signaling pathway in the treatment of acute kidney injury. Pharmacol Res, 2020, 161: 105121.
DOI:10.1016/j.phrs.2020.105121
16.
Chen LJ, Ning JZ, Cheng F, et al. Comparison of Intraperitoneal and Intratesticular GYY4137 Therapy for the Treatment of Testicular Ischemia Reperfusion Injury in Rats. Curr Med Sci, 2020, 40(2): 332-338.
DOI:10.1007/s11596-020-2180-6
17.
Yurinskaya MM, Krasnov GS, Kulikova DA, et al. H2S counteracts proinflammatory effects of LPS through modulation of multiple pathways in human cells. Inflamm Res, 2020, 69(5): 481-495.
DOI:10.1007/s00011-020-01329-x
18.
Kang SC, Sohn EH, Lee SR. Hydrogen Sulfide as a Potential Alternative for the Treatment of Myocardial Fibrosis. Oxid Med Cell Longev, 2020, 2020: 4105382.
DOI:10.1155/2020/4105382
19.
Soo E, Marsh C, Steiner R, et al. Optimizing organs for transplantation; advancements in perfusion and preservation methods. Transplant Rev (Orlando), 2020, 34(1): 100514.
DOI:10.1016/j.trre.2019.100514
20.
Zheng Q, Pan L, Ji Y. H 2S protects against diabetes-accelerated atherosclerosis by preventing the activation of NLRP3 inflammasome. J Biomed Res, 2019, 34(2): 94-102.
DOI:10.7555/JBR.33.20190071
21.
Newton TD, Pluth MD. Development of a hydrolysis-based small-molecule hydrogen selenide (H2Se) donor. Chem Sci, 2019, 10(46): 10723-10727.
DOI:10.1039/c9sc04616j
22.
Luo H, Song S, Chen Y, et al. Inhibitor 1 of Protein Phosphatase 1 Regulates Ca2+/Calmodulin-Dependent Protein Kinase II to Alleviate Oxidative Stress in Hypoxia-Reoxygenation Injury of Cardiomyocytes. Oxid Med Cell Longev, 2019, 2019: 2193019.
DOI:10.1155/2019/2193019
Chen Z, Tang J, Wang P, et al. GYY4137 Attenuates Sodium Deoxycholate-Induced Intestinal Barrier Injury Both In Vitro and In Vivo. Biomed Res Int, 2019, 2019: 5752323.
DOI:10.1155/2019/5752323
25.
Zheng W, Liu C. The cystathionine γ-lyase/hydrogen sulfide pathway mediates the trimetazidine-induced protection of H9c2 cells against hypoxia/reoxygenation-induced apoptosis and oxidative stress. Anatol J Cardiol, 2019, 22(3): 102-111.
DOI:10.14744/AnatolJCardiol.2019.83648
26.
Van Dingenen J, Pieters L, Vral A, et al. The H2S-Releasing Naproxen Derivative ATB-346 and the Slow-Release H2S Donor GYY4137 Reduce Intestinal Inflammation and Restore Transit in Postoperative Ileus. Front Pharmacol, 2019, 10: 116.
DOI:10.3389/fphar.2019.00116
27.
Wang W, Liu H, Lu Y, et al. Controlled-releasing hydrogen sulfide donor based on dual-modal iron oxide nanoparticles protects myocardial tissue from ischemia-reperfusion injury. Int J Nanomedicine, 2019, 14: 875-888.
DOI:10.2147/IJN.S186225
28.
Cao X, Zhang W, Moore PK, et al. Protective Smell of Hydrogen Sulfide and Polysulfide in Cisplatin-Induced Nephrotoxicity. Int J Mol Sci, 2019, 20(2): 313.
DOI:10.3390/ijms20020313
29.
Cao X, Ding L, Xie ZZ, et al. A Review of Hydrogen Sulfide Synthesis, Metabolism, and Measurement: Is Modulation of Hydrogen Sulfide a Novel Therapeutic for Cancer?. Antioxid Redox Signal, 2019, 31(1): 1-38.
DOI:10.1089/ars.2017.7058
30.
Merz T, Lukaschewski B, Wigger D, et al. Interaction of the hydrogen sulfide system with the oxytocin system in the injured mouse heart. Intensive Care Med Exp, 2018, 6(1): 41.
DOI:10.1186/s40635-018-0207-0
31.
Zhang L, Wang Y, Li Y, et al. Hydrogen Sulfide (H2S)-Releasing Compounds: Therapeutic Potential in Cardiovascular Diseases. Front Pharmacol, 2018, 9: 1066.
DOI:10.3389/fphar.2018.01066
32.
Zhang Y, Liu X, Zhang L, et al. Metformin Protects against H2O2-Induced Cardiomyocyte Injury by Inhibiting the miR-1a-3p/GRP94 Pathway. Mol Ther Nucleic Acids, 2018, 13: 189-197.
DOI:10.1016/j.omtn.2018.09.001
33.
Corsello T, Komaravelli N, Casola A. Role of Hydrogen Sulfide in NRF2- and Sirtuin-Dependent Maintenance of Cellular Redox Balance. Antioxidants (Basel), 2018, 7(10): 129.
DOI:10.3390/antiox7100129
34.
Woods JJ, Cao J, Lippert AR, et al. Characterization and Biological Activity of a Hydrogen Sulfide-Releasing Red Light-Activated Ruthenium(II) Complex. J Am Chem Soc, 2018, 140(39): 12383-12387.
DOI:10.1021/jacs.8b08695
35.
Zhou X, Tang S, Hu K, et al. DL-Propargylglycine protects against myocardial injury induced by chronic intermittent hypoxia through inhibition of endoplasmic reticulum stress. Sleep Breath, 2018, 22(3): 853-863.
DOI:10.1007/s11325-018-1656-0
36.
Zeng C, Jiang W, Zheng R, et al. Cardioprotection of tilianin ameliorates myocardial ischemia-reperfusion injury: Role of the apoptotic signaling pathway. PLoS One, 2018, 13(3): e0193845.
DOI:10.1371/journal.pone.0193845
37.
Ning JZ, Li W, Cheng F, et al. The protective effects of GYY4137 on ipsilateral testicular injury in experimentally varicocele-induced rats. Exp Ther Med, 2018, 15(1): 433-439.
DOI:10.3892/etm.2017.5417
38.
Meng G, Zhao S, Xie L, et al. Protein S-sulfhydration by hydrogen sulfide in cardiovascular system. Br J Pharmacol, 2018, 175(8): 1146-1156.
DOI:10.1111/bph.13825
39.
Peng Q, Wang X, Wu K, et al. Irisin attenuates H2O2-induced apoptosis in cardiomyocytes via microRNA-19b/AKT/mTOR signaling pathway. Int J Clin Exp Pathol, 2017, 10(7): 7707-7717.
40.
Wang M, Tang W, Zhu YZ. An Update on AMPK in Hydrogen Sulfide Pharmacology. Front Pharmacol, 2017, 8: 810.
DOI:10.3389/fphar.2017.00810
41.
Szabo C, Papapetropoulos A. International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors. Pharmacol Rev, 2017, 69(4): 497-564.
DOI:10.1124/pr.117.014050
42.
Pang Z, Zhao W, Yao Z. Cardioprotective Effects of Nicorandil on Coronary Heart Disease Patients Undergoing Elective Percutaneous Coronary Intervention. Med Sci Monit, 2017, 23: 2924-2930.
DOI:10.12659/msm.902324
43.
Sun X, Wang W, Dai J, et al. A Long-Term and Slow-Releasing Hydrogen Sulfide Donor Protects against Myocardial Ischemia/Reperfusion Injury. Sci Rep, 2017, 7(1): 3541.
DOI:10.1038/s41598-017-03941-0
44.
Sun Y, Huang Y, Yu W, et al. Sulfhydration-associated phosphodiesterase 5A dimerization mediates vasorelaxant effect of hydrogen sulfide. Oncotarget, 2017, 8(19): 31888-31900.
DOI:10.18632/oncotarget.16649
45.
Yuan S, Shen X, Kevil CG. Beyond a Gasotransmitter: Hydrogen Sulfide and Polysulfide in Cardiovascular Health and Immune Response. Antioxid Redox Signal, 2017, 27(10): 634-653.
DOI:10.1089/ars.2017.7096
46.
Magierowski M, Magierowska K, Hubalewska-Mazgaj M, et al. Exogenous and Endogenous Hydrogen Sulfide Protects Gastric Mucosa against the Formation and Time-Dependent Development of Ischemia/Reperfusion-Induced Acute Lesions Progressing into Deeper Ulcerations. Molecules, 2017, 22(2): 295.
DOI:10.3390/molecules22020295
47.
Bazhanov N, Escaffre O, Freiberg AN, et al. Broad-Range Antiviral Activity of Hydrogen Sulfide Against Highly Pathogenic RNA Viruses. Sci Rep, 2017, 7: 41029.
DOI:10.1038/srep41029
48.
Cao X, Bian JS. The Role of Hydrogen Sulfide in Renal System. Front Pharmacol, 2016, 7: 385.
DOI:10.3389/fphar.2016.00385
49.
Dugbartey GJ, Peppone LJ, de Graaf IA. An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures. Toxicology, 2016, 371: 58-66.
DOI:10.1016/j.tox.2016.10.001
50.
Haase T, Börnigen D, Müller C, et al. Systems Medicine as an Emerging Tool for Cardiovascular Genetics. Front Cardiovasc Med, 2016, 3: 27.
DOI:10.3389/fcvm.2016.00027
51.
Tian XH, Liu CL, Jiang HL, et al. Cardioprotection provided by Echinatin against ischemia/reperfusion in isolated rat hearts. BMC Cardiovasc Disord, 2016, 16: 119.
DOI:10.1186/s12872-016-0294-3
52.
Xu J, Tang Y, Bei Y, et al. miR-19b attenuates H2O2-induced apoptosis in rat H9C2 cardiomyocytes via targeting PTEN. Oncotarget, 2016, 7(10): 10870-8.
DOI:10.18632/oncotarget.7678
53.
Singh SB, Lin HC. Hydrogen Sulfide in Physiology and Diseases of the Digestive Tract. Microorganisms, 2015, 3(4): 866-89.
DOI:10.3390/microorganisms3040866
Authors and Reviewers
DownLoad:
